Your browser doesn't support javascript.
loading
Advances in prostate-specific membrane antigen targeted therapies for prostate cancer / 中华男科学杂志
Zhonghua nankexue ; Zhonghua nankexue;(12): 547-551, 2010.
Article de Zh | WPRIM | ID: wpr-252785
Bibliothèque responsable: WPRO
ABSTRACT
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.
Sujet(s)
Texte intégral: 1 Indice: WPRIM Sujet Principal: Tumeurs de la prostate / Thérapeutique / Thérapie génétique / Radioimmunothérapie / Glutamate carboxypeptidase II / Traitement médicamenteux / Immunothérapie / Antigènes de surface Limites du sujet: Humans / Male langue: Zh Texte intégral: Zhonghua nankexue Année: 2010 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Tumeurs de la prostate / Thérapeutique / Thérapie génétique / Radioimmunothérapie / Glutamate carboxypeptidase II / Traitement médicamenteux / Immunothérapie / Antigènes de surface Limites du sujet: Humans / Male langue: Zh Texte intégral: Zhonghua nankexue Année: 2010 Type: Article